Related Experiment Video
Updated: Jan 23, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Mantle Cell Lymphoma: Current and Emerging Treatment Strategies and Unanswered Questions
Benjamin Diamond1, Anita Kumar2
1Lymphoma Department, MSKCC, 1275 York Avenue, Box 468, New York, NY 10065, USA; Department of Medicine, Medical Oncology, New York, NY, USA.
Abstract:
Mantle cell lymphoma (MCL) is biologically and clinically heterogeneous with no clear standard of care. Overexpression of cyclin D1 is a hallmark of MCL. Evolving characterization of other molecular drivers explain a variety of disease phenotypes. These molecular profiles challenge risk stratification techniques. TP53-deleted disease is associated with adverse outcomes. Frontline treatment programs include intensive chemoimmunotherapy and autologous stem cell transplantation. Minimal residual disease may change management of MCL and guide therapy. As commonly dysregulated pathways become enumerated, novel biologically targeted agents and their combinations have been developed that will increasingly replace older, more toxic, and less efficacious regimens.
Related Concept Videos
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Emerging Adulthood
Introduction Cardiac Emergencies
Electrical Current
Applications of GIS: Disaster Management and Emergency Response
Significance of Displacement Current

